GSK Pursuing Late-Stage Inflammatory Bowel Disease Treatment With ChemoCentryx
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration includes potential payments of up to $1.5 bil. for co-development rights to Traficet-EN and other chemokine and chemoattractant receptors.
You may also be interested in...
GSK’s Center Of Excellence For External Drug Discovery Head Maxine Gowen: An Interview With “The Pink Sheet” DAILY
Company's approach to biotech deals differs from big pharma competitors, Gowen says.
GSK’s Center Of Excellence For External Drug Discovery Head Maxine Gowen: An Interview With “The Pink Sheet” DAILY
Company's approach to biotech deals differs from big pharma competitors, Gowen says.
Pfizer Gains Anti-Inflammatory Compound Development Rights Through Incyte Deal
Under the agreement for CCR2 antagonists, Incyte will maintain rights to multiple sclerosis and a second undisclosed indication.